- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04279457
Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System (Dye-Vert Plus)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures associated with Contrast-induced nephropathy (CIN). The reported incidence of contrast induced nephropathy (CIN) in high-risk patients following CAG varies from 10% to 30%1. The development of CIN after diagnostic coronary angiography and/or percutaneous coronary intervention (PCI) is associated with prolonged hospitalization and a remarkable increase in morbidity, early and late mortality and costs. The high rate of CIN in post-PCI patients could be related either to the patient (advanced age, previous CKD, diabetes, dehydration, and concomitant use of other nephrotoxic drugs) or procedure related (intra-arterial route of administration, use of high osmolar CM, repeated exposure to contrast within 48 h, volume of contrast used, etc.)2-5. Several strategies to prevent or treat CIN have been developed, including hydration, N-acetyl-cysteine, statins, ascorbic acid, bicarbonate, aminophylline, forced diuresis, renal replacement therapy, and choice of lowosmolarity or alternative agents, but one of the most obvious means is to minimize contrast volume. Patients that have a serum creatinine of > 1.5mg/dl and an eGFR < 60ml/min might be at higher risk for AKIs. In quarter one of 2018, CAMC's in-hospital risk-adjusted acute kidney injury for patients undergoing PCI was 10.64, and the US 50th percentile was 6.476. The goal of this study is to reduce in-hospital risk-adjusted acute kidney injury for patients undergoing PCI, below the US 50th, percentile-based NCDR quarterly results of the Cath-PCI registry by quarter one of 2020.
CIN is one of the leading causes of acute kidney injury at Charleston Area Medical Center it is imperative to take steps to prevent it. CIN is associated with a 13% increase in one- year mortality rate when comparing patients without CIN. Studies have also shown an increase in inpatient length of stay and substantial increase cost for patients who experienced CIN. The economic burden associated with CIN is high, the average in-hospital cost of CIN is $10,345 7. Adopting targeted interventions will reduce the incidence of CIN and the overall economic burden at Charleston Area Medical Center.
This trial is aimed at observing whether the use of the monitoring system Dye-Vert PLUS in conjugation with implementing a pre-hydration protocol on patients with high risk for CIN admitted for cardiac angiography and/or interventional cath lab procedures may reduce the incidence of CIN. An additional aim of the study will be to assess if use of the Dye-Vert PLUS monitoring system reduces the use of mean contrast media given in high-risk patients. Additional aims of this initiative will be to evaluate contrast-related complications, such as hypersensitivity reactions, as well as the associated impact of contrast-related complications on hospital health 3 care economics. This initiative will strive to incorporate clinical practice guidelines from SCAI Expert Consensus Statement: 2016 Best Practices in the Cardiac Catheterization Laboratory related to patient risk screening, pre-procedure hydration, and minimizing contrast media dose used.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Frank H Annie, PhD
- Phone Number: 304-388-9921
- Email: frank.h.annie@camc.org
Study Locations
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Recruiting
- CAMC Health Education and Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria:
- 18 years of age or older
- Scheduled to undergo CAG and/or PCI
- Baseline estimated glomerular filtration rate (eGFR) of ≥20 and ≤60 mL/ min/1.73 m2
- Serum creatinine > 1.5mg/dl
- Obtaining a Cardiac catheterization.
- HTN/Diabetes
- Inpatient and outpatient
Exclusion Criteria:
Exclusion criteria:
- 91 years of age or older
- Serum creatinine < 1.5mg/dl
- eGFR > 60ml/min
- Pregnancy
- Dialysis
- Dye Allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standardized Hydration protocol
These cases will follow Charleston Area Medical Centers standard Hydration protocol
|
hydration protocol based up on the Poseidon protocol
|
ACTIVE_COMPARATOR: Hydration + Device
These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
|
The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure.
At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring of AKI
Time Frame: 3 days
|
Determined by GFR levels
|
3 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-637
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AKI (Acute Kidney Injury) Due to Trauma
-
Ain Shams UniversityCompletedAKI (Acute Kidney Injury) Due to TraumaEgypt
-
Assiut UniversityNot yet recruitingAcute Kidney Injury Due to covid_19Egypt
-
Mahmoud Kamel Mohamed Abd elhaqNot yet recruitingAcute Kidney Injury Due to Sepsis
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Virginia Commonwealth UniversityAbiomed Inc.WithdrawnContrast-induced Acute Kidney Injury (CI-AKI)
-
University of Sao PauloInstituto Dante Pazzanese de CardiologiaRecruitingAcute Kidney Injury Due to Circulatory FailureBrazil
-
Second Affiliated Hospital of Soochow UniversityRecruitingPatient Admitted to Hospital With Acute Kidney Injury Due to SepsisChina
Clinical Trials on Standardized hydration protocol
-
State University of New York at BuffaloCompletedHyperthermia | Dehydration (Physiology)United States
-
Maastricht University Medical CenterCompletedDiabetes Mellitus, Type 2 | Insulin ResistanceNetherlands
-
Luiz Carlos Marques VanderleiCompleted
-
Maastricht UniversityMaastricht University Medical CenterCompletedDiabetes Mellitus, Type 2 | Insulin ResistanceNetherlands
-
Mackay Memorial HospitalNational Taiwan UniversityCompleted
-
University of California, San DiegoRady Children's Hospital, San DiegoRecruitingNeonatal Respiratory FailureUnited States
-
Riphah International UniversityHelping Hand Institute of Rehabilitation SciencesRecruiting
-
Riphah International UniversityCompletedPost-cardiac SurgeryPakistan
-
University Hospital Inselspital, BerneUniversity of BernCompletedNicotine DependenceSwitzerland
-
Universidad San JorgeMontpellier ClinicCompletedSubacromial ImpingementSpain